Deciding whether to partner an important late-stage asset or commercialize it independently is a biotech dilemma as old as the industry itself. An emerging company aims to maintain as large a share of equity in its lead asset as it can. At the same time, a biotech needs to assess whether tapping the resources of a larger and/or more experienced organization would maximize the product’s commercial success. Making the best decision on whether to partner and with whom will depend on many factors. This second installment of our “Growing Up Biotech" series identifies the key factors around a pivotal question posed when launching your product: to partner or not to partner?